Literature DB >> 14746861

One in 10 ovarian cancer patients carry germ line BRCA1 or BRCA2 mutations: results of a prospective study in Southern Sweden.

S Malander1, M Ridderheim, A Måsbäck, N Loman, U Kristoffersson, H Olsson, M Nilbert, A Borg.   

Abstract

At least 10% of all ovarian cancers are estimated to have a hereditary background. Hereditary breast-ovarian cancer (HBOC) due to mutations in the BRCA genes is a major cause of hereditary ovarian cancer, although its frequency and relationship to age and family history in unselected series of ovarian cancers is not completely known. We report here the results of a full mutational screening analysis for germ line BRCA1 and BRCA2 mutations in 161 patients with invasive epithelial ovarian carcinomas. Age at diagnosis ranged from 22 to 82 years (mean 59 years). Deleterious (frame-shift, nonsense and missense) mutations were detected in 13/161 (8%) of the patients and affected BRCA1 in 12 cases and BRCA2 in one case. Four additional missense variants (one in BRCA1 and three in BRCA2) with a possible association with an increased risk ovarian cancer were revealed, resulting in a total frequency of BRCA gene alterations of 17/161 (11%). The 13 patients with deleterious mutations had a mean age of 57 years (range 41-76 years) and only three of these patients were below 50 years of age. A family history of at least one breast cancer and/or ovarian cancer was reported in all but 1 of the patients with BRCA mutations compared with only 24% of patients without mutations. Our findings in this prospective study confirm approximately 1 in 10 patients with ovarian cancer carry a germ line BRCA gene mutation associated with HBOC, and also indicate that a large number of these patients are over 50 years of age at diagnosis.

Entities:  

Mesh:

Year:  2004        PMID: 14746861     DOI: 10.1016/j.ejca.2003.09.016

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  31 in total

1.  On the origin and diffusion of BRCA1 c.5266dupC (5382insC) in European populations.

Authors:  Nancy Hamel; Bing-Jian Feng; Lenka Foretova; Dominique Stoppa-Lyonnet; Steven A Narod; Evgeny Imyanitov; Olga Sinilnikova; Laima Tihomirova; Jan Lubinski; Jacek Gronwald; Bohdan Gorski; Thomas v O Hansen; Finn C Nielsen; Mads Thomassen; Drakoulis Yannoukakos; Irene Konstantopoulou; Vladimir Zajac; Sona Ciernikova; Fergus J Couch; Celia M T Greenwood; David E Goldgar; William D Foulkes
Journal:  Eur J Hum Genet       Date:  2010-12-01       Impact factor: 4.246

2.  Occurrence of both breast and ovarian cancer in a woman is a marker for the BRCA gene mutations: a population-based study from western Sweden.

Authors:  Zakaria Einbeigi; Annika Bergman; Jeanne M Meis-Kindblom; Anna Flodin; Cecilia Bjursell; Tommy Martinsson; Lars-Gunnar Kindblom; Jan Wahlström; Arne Wallgren; Margareta Nordling; Per Karlsson
Journal:  Fam Cancer       Date:  2007       Impact factor: 2.375

3.  BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.

Authors:  Kathryn Alsop; Sian Fereday; Cliff Meldrum; Anna deFazio; Catherine Emmanuel; Joshy George; Alexander Dobrovic; Michael J Birrer; Penelope M Webb; Colin Stewart; Michael Friedlander; Stephen Fox; David Bowtell; Gillian Mitchell
Journal:  J Clin Oncol       Date:  2012-06-18       Impact factor: 44.544

4.  A clinical perspective on genetic counseling and testing during end of life care for women with recurrent progressive ovarian cancer: opportunities and challenges.

Authors:  Molly S Daniels; Jennifer K Burzawa; Amanda C Brandt; Kathleen M Schmeler; Karen H Lu
Journal:  Fam Cancer       Date:  2011-06       Impact factor: 2.375

5.  Patient preferences and National Health Service costs: a cost-consequences analysis of cancer genetic services.

Authors:  Gethin L Griffith; Rhiannon Tudor Edwards; J Mark G Williams; Jonathon Gray; Val Morrison; Clare Wilkinson; Jim Turner; Barbara France; Paul Bennett
Journal:  Fam Cancer       Date:  2008-09-27       Impact factor: 2.375

Review 6.  The contribution of BRCA1 and BRCA2 to ovarian cancer.

Authors:  Susan J Ramus; Simon A Gayther
Journal:  Mol Oncol       Date:  2009-02-10       Impact factor: 6.603

7.  Family history of malignancies and risk of breast cancer: prospective data from the Shanghai women's health study.

Authors:  Briseis A Kilfoy; Yawei Zhang; Xiao-Ou Shu; Yu-Tang Gao; Bu-Tian Ji; Gong Yang; Hong Lan Li; Nathaniel Rothman; Wong-Ho Chow; Wei Zheng
Journal:  Cancer Causes Control       Date:  2008-06-25       Impact factor: 2.506

Review 8.  A review of the clinical relevance of mismatch-repair deficiency in ovarian cancer.

Authors:  Tuya Pal; Jenny Permuth-Wey; Thomas A Sellers
Journal:  Cancer       Date:  2008-08-15       Impact factor: 6.860

9.  Association between IHC and MSI testing to identify mismatch repair-deficient patients with ovarian cancer.

Authors:  Ji-Hyun Lee; Deborah Cragun; Zachary Thompson; Domenico Coppola; Santo V Nicosia; Mohammad Akbari; Shiyu Zhang; John McLaughlin; Steven Narod; Joellen Schildkraut; Thomas A Sellers; Tuya Pal
Journal:  Genet Test Mol Biomarkers       Date:  2014-03-04

10.  CHEK2 1100 delC mutation in Russian ovarian cancer patients.

Authors:  Nadezhda Yu Krylova; Daria N Ponomariova; Natalia Yu Sherina; Natalia Yu Ogorodnikova; Denis A Logvinov; Natalia V Porhanova; Oksana S Lobeiko; Adel F Urmancheyeva; Sergey Ya Maximov; Alexandr V Togo; Evgeny N Suspitsin; Evgeny N Imyanitov
Journal:  Hered Cancer Clin Pract       Date:  2007-09-15       Impact factor: 2.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.